Generics - North America


Current filters:

North America

Popular Filters

2701 to 2717 of 2717 results

Watson 1st-qtr 2011 net revenue Increases 2.3% to $877 million


USA-based generics and specialty drugmaker Watson Pharmaceuticals (NYSE: WPI) reported net revenue of…

FinancialGenericsPharmaceuticalWatson Pharmaceuticals

US FDA not ready to approve Eisai Aricept Patch; Lipacreon and Halaven OKed in Japan


Japanese drug major Eisai (TYO: 4523) says that the US Food and Drug Administration has issued a Complete…

AriceptAsia-PacificEisaiHalavenLipacreonNeurologicalNorth AmericaOncologyPfizerPharmaceuticalRegulation

AstraZeneca and Pozen sue Dr Reddy’s over Vimovo patent


Anglo-Swedish drug major AstraZeneca (LSE: AZN and USA-based Pozen (Nasdaq; POZN) have filed a law suit…

Anti-Arthritics/RheumaticsAstraZenecaDr Reddy's LaboratoriesGenericsLegalNorth AmericaPatentsPharmaceuticalPozenVimovo

Hospira’s first-quarter 2011 results beat forecasts, helped by generic Taxotere


Specialty drugmaker Hospira (NYSE: HSP) yesterday reported results for the first quarter ended March…


New biopharma firm to accelerate vaccines and protein therapeutics delivery


USA-based Caliber Biotherapeutics has announced the opening of the world's largest plant-made pharmaceutical…

Antibiotics and Infectious diseasesBiotechnologyCaliber BiotherapeuticsMarkets & MarketingNorth AmericaOncologyPharmaceuticalVaccines

AstraZeneca debuts vandetanib for medullary thyroid cancer in USA


Anglo-Swedish drug major AstraZeneca (LSE: AZN) said yesterday that its orphan drug vandetanib is now…

AstraZenecaMarkets & MarketingNorth AmericaOncologyPharmaceuticalRare diseasesvandetanibZactima

Roche gets FDA OK for use of Rituxan to treat two rare disorders


The US Food and Drug Administration yesterday approved Swiss drug major Roche (ROG: SIX) subsidiary Genentech’s…

North AmericaPharmaceuticalRare diseasesRegulationRituxanRoche

Growth in US spending on medicines slows to 2.3% in 2010, says IMS


Growth in US spending on medicines slows to 2.3% in 2010, says IMS

GenericsHealthcareMarkets & MarketingNorth AmericaPharmaceuticalPricing

Regeneron gains US FDA priority review for VEGF Trap-Eye in wet AMD


USA-based Regeneron Pharmaceuticals (Nasdaq: REGN) says that the US Food and Drug Administration has…

BayerNorth AmericaOphthalmicsPharmaceuticalRegeneronRegulationVEGF Trap-Eye

Alapis enters MoU with China's CSPC Pharma on areas of collaboration


Greek drugmaker Alapis SA (APSHF: PK) has signed a memorandum of understanding (MoU) with one of China's…

AlapisCSPC PharmaceuticalGenericsLicensing

US FDA calls for additional study on Lilly’s EPI drug candidate Solpura


In what is a disappointment, but probably no surprise to US drug major Eli Lilly (NYSE: LLY), the company…

Eli LillyNorth AmericaPharmaceuticalRegulationSolpura

US FDA approves Roche’s Actemra for systemic juvenile idiopathic arthritis


Genentech, part of Swiss drug major Roche (ROG: SIX), says the US Food and Drug Administration has approved…

ActemraAnti-Arthritics/RheumaticsNorth AmericaPharmaceuticalRare diseasesRegulationRoche

78% of US health plans will reimburse for emerging oral therapies for multiple sclerosis, study suggests


A large percentage of US health plans (78%) will reimburse for emerging oral disease-modifying therapies…

GilenyaNeurologicalNorth AmericaNovartisPharmaceuticalPricing

2701 to 2717 of 2717 results

Back to top